Current practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study.

ABSTRACT:

Background

Given that pathologists now frequently assess pathologic response following neoadjuvant or perioperative chemoimmunotherapy for NSCLC, we set up a multicentre study to evaluate the current practice of regression grading in Germany (Re-GraDE NSCLC).

Methods

133 cases of NSCLC resection specimens following chemoimmunotherapy (IO) were collected from 9 high-volume lung cancer centres in Germany. Case characteristics were obtained from pathology reports/electronic medical records. In 107 cases, pretreatment biopsies were available on-site.

Results

Residual viable tumour (% RVT) was commonly used to measure therapy response (106/133 resection specimens, 79.7%). The entire tumour bed was submitted for histology in 55.6% of cases; however, in 18%, a tumour bed of

SUBMITTER: Elsner F 

PROVIDER: S-EPMC12605775 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature